Efficacy of statin therapy on arterial wall inflammation in patients with Chronic Kidney Disease
Recruiting
- Conditions
- chronic kidney disease stages 3 and 4, defined by a eGFR of 15-60 ml min
- Registration Number
- NL-OMON22577
- Lead Sponsor
- Academical Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 17
Inclusion Criteria
1. Aged 50 years or older
2. CKD stages 3 and 4 (eGFR: 15-60 ml/min per 1.73m2)
Exclusion Criteria
1. Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
2. Standard contra-indications to 18F-FDG PET, and CT based on physicians experience and current practices
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the anti-inflammatory effects of 3 months statin therapy on vessel wall inflammation by means of FDG PET/CT in patients with CKD.
- Secondary Outcome Measures
Name Time Method To assess differences in the innate immune system in patients with CKD before and after treatment with statins.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie statin-induced reduction of arterial wall inflammation in chronic kidney disease?
How does statin therapy compare to standard-of-care treatments for arterial inflammation in CKD stages 3 and 4 patients?
Which biomarkers correlate with response to statin therapy in patients with eGFR 15-60 ml/min undergoing arterial inflammation treatment?
What are the potential adverse events associated with statin use in chronic kidney disease and how can they be managed?
Are there combination therapies or alternative drugs that enhance statin efficacy in reducing arterial inflammation for CKD patients?